EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
It may take some time to load the article after you tap to read more.
Tap here to know more...... DailyMed (which is maintained by National Library of Medicine)
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c&type=display#S1
